Filing Details
- Accession Number:
- 0000950170-24-025036
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-04 17:49:33
- Reporting Period:
- 2024-02-29
- Accepted Time:
- 2024-03-04 17:49:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1805387 | Cerevel Therapeutics Holdings Inc. | CERE | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1197018 | Anthony N Coles | C/O Cerevel Therapeutics Holdings, Inc. 222 Jacobs Street, Suite 200 Cambridge MA 02141 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-02-29 | 50,000 | $3.50 | 65,638 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-02-29 | 50,000 | $41.16 | 15,638 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2024-02-29 | 50,000 | $0.00 | 50,000 | $3.50 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
2,402,417 | 2028-12-24 | No | 4 | M | Direct |
Footnotes
- These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.00 to $41.28. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The option is fully vested and exercisable.